CO5640134A2 - Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x - Google Patents

Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x

Info

Publication number
CO5640134A2
CO5640134A2 CO06005238A CO06005238A CO5640134A2 CO 5640134 A2 CO5640134 A2 CO 5640134A2 CO 06005238 A CO06005238 A CO 06005238A CO 06005238 A CO06005238 A CO 06005238A CO 5640134 A2 CO5640134 A2 CO 5640134A2
Authority
CO
Colombia
Prior art keywords
alkyl
phenyl
optionally substituted
group
pyridylmethyl
Prior art date
Application number
CO06005238A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Holm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5640134A2 publication Critical patent/CO5640134A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CO06005238A 2003-07-11 2006-01-20 Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x CO5640134A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
CO5640134A2 true CO5640134A2 (es) 2006-05-31

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06005238A CO5640134A2 (es) 2003-07-11 2006-01-20 Derivados de pirrol-2,5-ditiona como moduladores de receptor hepatico x

Country Status (25)

Country Link
US (1) US20060189663A1 (cg-RX-API-DMAC7.html)
EP (1) EP1646625B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007521313A (cg-RX-API-DMAC7.html)
KR (1) KR20060034284A (cg-RX-API-DMAC7.html)
CN (1) CN100478340C (cg-RX-API-DMAC7.html)
AR (1) AR045720A1 (cg-RX-API-DMAC7.html)
AT (1) ATE399776T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004256000B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412479A (cg-RX-API-DMAC7.html)
CA (1) CA2532068A1 (cg-RX-API-DMAC7.html)
CO (1) CO5640134A2 (cg-RX-API-DMAC7.html)
DE (1) DE602004014772D1 (cg-RX-API-DMAC7.html)
ES (1) ES2308205T3 (cg-RX-API-DMAC7.html)
GB (1) GB0316237D0 (cg-RX-API-DMAC7.html)
IL (1) IL172759A0 (cg-RX-API-DMAC7.html)
IS (1) IS8291A (cg-RX-API-DMAC7.html)
MX (1) MXPA06000447A (cg-RX-API-DMAC7.html)
NO (1) NO20060080L (cg-RX-API-DMAC7.html)
RU (1) RU2006102129A (cg-RX-API-DMAC7.html)
SA (1) SA04250203B1 (cg-RX-API-DMAC7.html)
TW (1) TW200507836A (cg-RX-API-DMAC7.html)
UA (1) UA82108C2 (cg-RX-API-DMAC7.html)
UY (1) UY28407A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005005416A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600229B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
MX2007008370A (es) 2005-01-10 2007-08-21 Astrazeneca Ab Derivados de 1,1-dioxidos de isotiazol-3 (2h) -ona como moduladores del receptor del higado x.
ES2438739T3 (es) * 2005-06-28 2014-01-20 Daiichi Sankyo Company, Limited Procedimiento de prueba de ligando LXR
WO2008024724A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US20100056444A1 (en) * 2006-10-12 2010-03-04 Sven Martin Jacobson Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
CA3123813C (en) * 2007-12-04 2024-10-08 Remedy Pharmaceuticals, Inc. IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック, インコーポレイテッド Mekキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
CA2811145A1 (en) 2010-09-07 2012-03-15 Snu R&Db Foundation Sesterterpene compound and use thereof
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ,インコーポレーテッド 金属塩及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527419A (ja) * 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Gsk−3阻害物質としてのピロール−2,5−ジオン類
EP1212065A4 (en) * 1999-07-08 2004-02-11 Tularik Inc COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL

Also Published As

Publication number Publication date
BRPI0412479A (pt) 2006-09-19
AU2004256000B2 (en) 2007-07-26
ZA200600229B (en) 2007-04-25
AR045720A1 (es) 2005-11-09
US20060189663A1 (en) 2006-08-24
KR20060034284A (ko) 2006-04-21
EP1646625B1 (en) 2008-07-02
RU2006102129A (ru) 2006-08-27
TW200507836A (en) 2005-03-01
EP1646625A1 (en) 2006-04-19
CN1820003A (zh) 2006-08-16
UY28407A1 (es) 2005-02-28
NO20060080L (no) 2006-02-08
AU2004256000A1 (en) 2005-01-20
SA04250203B1 (ar) 2008-02-25
GB0316237D0 (en) 2003-08-13
WO2005005416A1 (en) 2005-01-20
ES2308205T3 (es) 2008-12-01
CN100478340C (zh) 2009-04-15
HK1088318A1 (en) 2006-11-03
IL172759A0 (en) 2006-04-10
JP2007521313A (ja) 2007-08-02
DE602004014772D1 (de) 2008-08-14
CA2532068A1 (en) 2005-01-20
UA82108C2 (uk) 2008-03-11
MXPA06000447A (es) 2006-04-07
ATE399776T1 (de) 2008-07-15
IS8291A (is) 2006-02-09

Similar Documents

Publication Publication Date Title
CO6160291A2 (es) Compuestos que modulan al receptor cb2
DE602004028229D1 (de) Prostaglandin analoge als ep4 rezeptor agonisten
IN2012DN04853A (cg-RX-API-DMAC7.html)
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
NO20082579L (no) Aza-substituert spiroderivat
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
CR7950A (es) Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas
WO2006087476A3 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
ES2586527T3 (es) Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
TW200617003A (en) Viral polymerase inhibitors
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
ATE510829T1 (de) Neue verbindungen als adenosin-a1-rezeptor- antagonisten
ATE417841T1 (de) Furanderivate als ep4-rezeptorantagonisten
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
WO2008116185A3 (en) Substituted pyrimidines as adenosine receptor antagonists
MX2012008147A (es) Derivados de pirrazolopiridina.
AR075586A1 (es) Proceso, purificacion y cristalizacion de 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea, inhibidor de pi3k/mtor
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra
CL2004000160A1 (es) Derivados de avermectina sustituidos en posicion 4' y 4'', composicion que los contiene, utiles como plaguicidas.
ATE396183T1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors

Legal Events

Date Code Title Description
FC Application refused